Key result
Therapeutic dose paracetamol for PDA closure linked to reversible acute liver failure in a preterm infant.
Why the study?
Does standard therapeutic dose paracetamol cause acute liver failure in extremely preterm neonates with patent ductus arteriosus?
Does standard therapeutic dose paracetamol cause acute liver failure in extremely preterm neonates with patent ductus arteriosus?
Standard therapeutic doses of paracetamol for PDA closure can cause acute liver failure in extremely preterm neonates, which is reversible with N-acetyl cysteine.
Alerts to hepatotoxicity risk from standard-dose paracetamol in extremely preterm infants; leaves open its safety for PDA closure pending larger studies.
We report the first case of standard therapeutic dose paracetamol for patent ductus arteriosus closure causing acute liver failure in an extremely preterm infant. After 5 days of treatment, he presented with jaundice, acute severe hepatitis and coagulopathy. Treatment with N-acetyl cysteine resulted in full recovery.
No takes yet. Share an insight, caveat, or question.
Raghu et al. (2022) studied this question. Standard therapeutic dose paracetamol for patent ductus arteriosus closure caused acute liver failure in an extremely preterm infant, which fully resolved with N-acetyl cysteine treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: